STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
chemistry

Mira Pharmaceuticals Approves Acquisition of SKNY, Creating $60M+ Biotech Platform

byLuca Blaumann
May 8, 2025
in Pharmaceuticals, Small-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Board approves merger following independent valuation; SKNY to contribute $5M in cash or assets at closing

Mira Pharmaceuticals (MIRA), a clinical-stage company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, has announced that its Board of Directors has unanimously approved the acquisition of SKNY Pharmaceuticals, Inc. The deal follows independent valuations of both companies and sets a combined enterprise value exceeding $60 million.

The strategic merger includes a $5 million contribution from SKNY to Mira in either cash or other assets, which will be transferred at closing. A filing with the U.S. Securities and Exchange Commission is underway to obtain shareholder approval.

According to independent analysis by Moore Financial Consulting, SKNY Pharmaceuticals was assigned an enterprise value of $30.5 million, based on the risk-adjusted net present value (rNPV) of its lead compound, SKNY-1. Mira itself was valued at $30 million, creating a solid foundation for a unified company with complementary pipelines and commercial potential.

“This merger brings together two pipelines, two market opportunities, and one unified strategy,” said Erez Aminov, CEO of Mira. “Our focus remains on developing first-in-class therapies that target critical and underserved health needs.”

The centerpiece of SKNY’s pipeline is SKNY-1, an investigational oral compound that modulates cannabinoid receptors CB1 and CB2, as well as monoamine oxidase B (MAO-B)—an enzyme linked to dopamine metabolism and addiction. The compound is being developed for both obesity and nicotine dependence, two global health challenges with limited treatment options.

Industry projections underscore the market potential:

  • The global weight loss drug market is expected to surpass $150 billion by 2030, with increasing demand for alternatives to injectable GLP-1 therapies (Reuters).
  • The U.S. smoking cessation market is forecast to grow from $28.11 billion in 2024 to $50.90 billion by 2030, at a CAGR of 10.4% (Grand View Research).

Dr. Angel, Mira’s Chief Scientific Advisor, emphasized the scientific rationale behind SKNY-1: “This is a uniquely designed molecule that addresses the biological complexity of both obesity and addiction. The early data are promising.”

Mira views the acquisition as a pivotal step toward building a scaled, innovation-driven platform focused on areas of urgent unmet need—backed by differentiated science and a clear commercial strategy.

You might like this article:Trump Crypto Advisor David Bailey Raises $300M for New Public Bitcoin Investment Firm

Tags: GrowthMIRAMoversNewsStock Market
Previous Post

Trump Crypto Advisor David Bailey Raises $300M for New Public Bitcoin Investment Firm

Next Post

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

Related Posts

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

byLuca Blaumann
November 10, 2026
0

Company reports $7.4 million in quarterly revenue, exits Bitcoin holdings, and strengthens its balance sheet with $54.5 million in cash...

KULR Secures $1 Million-Plus Battery Orders for U.S. Drone Dominance Program

byLuca Blaumann
October 1, 2026
0

Production orders strengthen KULR’s position in advanced drone systems, with deliveries scheduled through November 2026 KULR Technology Group (KULR) announced...

investing

Top Movers Today:

byLuca Blaumann
September 22, 2026
0

$LHSW $DCOY $GRML $JAGX $FLNA $LHSW - Lianhe Sowell International Group shares are trading higher after the company announced it...

Next Post

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

Latest News

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Based on Your Interest

investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026
Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026

Recommended

Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Artificial Intelligence

IonQ Revenue Surges 336% to Record $173.8 Million as Quantum Computing Demand Accelerates

November 6, 2026
Stoxpo

Follow us on social media:

Highlights

  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates
  • CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

November 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.